Will Ashworth

Will Ashworth

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

Wall Street’s Whisper List: 3 Stocks Primed for Public Frenzy

Investors like Wall Street whispers, a term used to describe analyst upgrades. Here are three stocks Wall Street is talking about.

3 Stocks to Buy to Ride the Wave of Skyrocketing Car Insurance Rates

Property and casualty firms raised their premiums over the past three years due to various reasons. These insurance stocks benefited.

The Top 3 Cannabis Stocks to Buy in March 2024

While some might consider those seeking the top cannabis stocks to buy gluttons for punishment, contrarians should like these possibilities.

Betting on Bitcoin: Does Coinbase Stock’s Surge Signal a Buy?

Bitcoin has exploded higher over the past month setting an all-time record. That’s excellent news for Coinbase Global and COIN stock.

Heat Pump Heroes: 3 Renewable Energy Stocks That Will Have You Seeing Green

The transition from fossil fuels to renewable energy has been a significant benefit to these three renewable energy stocks.

Financial Freedom Fighters: 3 Stocks to Liberate Your Portfolio

Stocks for financial freedom are generational companies that are well-run, growing fast, and focused on the future.

High-Yield Haven: 3 Top Stocks Offering 6.5% Returns or More

While some high-yield stocks are value traps, they can also be value plays. Knowing the difference is the key to investment success.

3 Reasons a Berkshire Hathaway Spin-Off Should Be Buffett’s Next Big Move 

With Warren Buffett effectively throwing in the towel on a significant acquisition, a Berkshire Hathaway spin-off becomes a logical next move.

Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits

Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.

Palantir Stock’s Buyback Bluff: Bold Move or Smoke Screen?  

Palantir’s had a $1 billion share repurchase program for the past seven months. It’s bought zero PLTR stock.